Veloxis Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health ... PR Newswire (press release) Mr. Koval will present an overview of the company and discuss top-line Phase 3 results of LCP-Tacro™, Veloxis' candidate to prevent organ transplant rejection. Based in Horsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, ... |
